Want to see ARTV full AI Analyst Report?
ARTV Stock Chart & Stats
$12.55
$0.32(3.02%)
At close: 4:00 PM EST
$12.55
$0.32(3.02%)
Day’s Range― - ―
52-Week Range$2.04 - $14.53
Previous CloseN/A
Volume23.16K
Average Volume (3M)618.72K
Market Cap
$457.21M
Enterprise Value$234.99M
Total Cash (Recent Filing)$86.78M
Total Debt (Recent Filing)$10.26M
Price to Earnings (P/E)―
Beta2.29
Next Earnings
Aug 27, 2026EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.55
Shares Outstanding48,588,200
10 Day Avg. Volume482,087
30 Day Avg. Volume618,723
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.95
Price to Sales (P/S)0.00
P/FCF Ratio-1.32
Enterprise Value/Market Cap0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-352.84
Enterprise Value/Ebitda-2.78
Forecast
1Y Price Target
$35.80Price Target Upside185.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.67
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Large $300M Equity RaiseThe $300M underwritten equity offering materially extends Artiva’s funding runway and increases capacity to execute planned Phase 3 and broader development activities without immediate capital raises. This structural capital reduces near-term liquidity risk and supports milestone-driven development.
FDA Phase 3 Alignment For AlloNKFDA alignment on a single Phase 3 registrational trial, combined with Phase 2 signals (71% ACR50 and favorable tolerability), materially improves regulatory and clinical development visibility. It creates a clearer path to potential approval and future commercialization, lowering program execution uncertainty.
Low Leverage ProfileModest debt relative to equity gives structural financial flexibility for a pre-revenue biotech. Low leverage reduces fixed financing costs and bankruptcy risk, preserving optionality to prioritize R&D spending and pursue regulatory milestones without large interest burdens.
Bears Say
High Cash BurnCash flow is deeply negative, with TTM operating cash flow and free cash flow both near -$78M to -$80M. Persistent high burn depletes resources and forces recurring financings to sustain development. Even with recent proceeds, continual outflows constrain strategic options and increase long-term financing risk.
Absent Recurring RevenueProfitability and revenue visibility are weak: a TTM net loss of -$87.1M and effectively no recent revenue mean Artiva cannot self-fund operations. Reliance on external capital until regulatory success increases execution risk and limits the company's ability to invest without dilutive financing.
Executive Transitions And Role ConsolidationRecent leadership changes concentrate responsibilities (CEO now principal financial officer), the CFO departed, and a new R&D head was hired with substantial pay. Such shifts can strain governance and operational continuity, distract management during critical late‑stage development, and raise short‑term execution risk.
Artiva Biotherapeutics, Inc. News
ARTV FAQ
What was Artiva Biotherapeutics, Inc.’s price range in the past 12 months?
Artiva Biotherapeutics, Inc. lowest stock price was $2.04 and its highest was $14.53 in the past 12 months.
What is Artiva Biotherapeutics, Inc.’s market cap?
Artiva Biotherapeutics, Inc.’s market cap is $457.21M.
When is Artiva Biotherapeutics, Inc.’s upcoming earnings report date?
Artiva Biotherapeutics, Inc.’s upcoming earnings report date is Aug 27, 2026 which is in 46 days.
How were Artiva Biotherapeutics, Inc.’s earnings last quarter?
Artiva Biotherapeutics, Inc. released its earnings results on May 08, 2026. The company reported -$0.95 earnings per share for the quarter, missing the consensus estimate of -$0.87 by -$0.08.
Is Artiva Biotherapeutics, Inc. overvalued?
According to Wall Street analysts Artiva Biotherapeutics, Inc.’s price is currently Undervalued.
Does Artiva Biotherapeutics, Inc. pay dividends?
Artiva Biotherapeutics, Inc. does not currently pay dividends.
What is Artiva Biotherapeutics, Inc.’s EPS estimate?
Artiva Biotherapeutics, Inc.’s EPS estimate is -0.63.
How many shares outstanding does Artiva Biotherapeutics, Inc. have?
Artiva Biotherapeutics, Inc. has 48,588,200 shares outstanding.
What happened to Artiva Biotherapeutics, Inc.’s price movement after its last earnings report?
Artiva Biotherapeutics, Inc. reported an EPS of -$0.95 in its last earnings report, missing expectations of -$0.87. Following the earnings report the stock price went down -13.019%.
Which hedge fund is a major shareholder of Artiva Biotherapeutics, Inc.?
Currently, no hedge funds are holding shares in ARTV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artiva Biotherapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.80 (185.26% Upside)
$35.80 (185.26% Upside)
Blogger Sentiment
Bullish
ARTV Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $103.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
438.54%
12-Months-Change
Fundamentals
Return on Equity
-73.16%
Trailing 12-Months
Asset Growth
-44.60%
Trailing 12-Months
Company Description
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
ARTV Stock 12 Month Forecast
Average Price Target
$35.80
▲(185.26% Upside)
Technical Analysis
Ownership Overview
55.18% Insiders
1.17% Mutual Funds
30.95% Other Institutional Investors
11.64% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---